logo-loader
viewOncimmune

Oncimmune has “substantially reduced” commercial risk for EarlyCDT cancer test, says broker

In a note initiating the biotech firm with a price target of 150p, the broker forecast £400,000 in revenues for the first half of the 2020 financial year and £800,000 for the second half

Oncimmune - Oncimmune has “substantially reduced” commercial risk for EarlyCDT cancer test, says broker
EarlyCDT is a test that aims to detect lung cancer at as early a stage as possible

Oncimmune Holdings PLC (LON:ONC) has “substantially reduced” the commercial launch risk for its EarlyCDT lung cancer test through a series of supply and licence deals, according to analysts at finnCap.

In a note initiating the biotech firm with a price target of 150p, the broker said the company’s business model reduced execution risk through supply and licence deals in the US and China, distribution agreements in 23 additional markets and “a diversifying pipeline of revenues”.

READ: Oncimmune Holdings draws down final tranche of IPF facility

As a result, they expected “early evidence of the revenue ramp” in the current year, predicting £400,000 in revenues for the first half of the 2020 financial year and £800,000 for the second half.

finnCap also expects Oncimmune to be cash flow positive by 2024, while its current cash balance, which provides funds until 2022, would provide “the time to deliver further meaningful valuation points”.

In late-afternoon trading on Friday, Oncimmune shares were 1% higher at 51p, a 66% discount to finnCap’s target price.

Quick facts: Oncimmune

Price: 47 GBX

AIM:ONC
Market: AIM
Market Cap: £29.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and...

on 1/11/19

2 min read